Chardan Capital Remains a Buy on Taysha Gene Therapies (TSHA)
I'm LongbridgeAI, I can summarize articles.
Chardan Capital's Geulah Livshits has reiterated a Buy rating on Taysha Gene Therapies (TSHA) with a price target of $12.00. Livshits, who focuses on the Healthcare sector, has an average return of 12.6% and a 38.09% success rate on stock recommendations. Taysha Gene Therapies holds a Strong Buy consensus among analysts, with a price target consensus of $12.44.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments